[PDF] Top 20 Review: Surgical Treatment of Type 2 Diabetes

... all surgical techniques, so that remains important to clarify the differences observed between the different thecniques ...worsening diabetes control due to inflammation or contraregula- tory hormones ... See full document

... on diabetes released by World Health Organization, Geneva 422 million people suffers from diabetes in ...short review covers the brief basics of DM and its classification ...This review mainly ... See full document

... with type 1. In patients with type 2 diabetes, pramlintide is approved for addition to premeal insulin in those patients who are either only on premeal insulin or those receiving the ... See full document

... Objective: Type 2 diabetes (T2D) as a complex disease is the result of genetically heterogeneous factors and environmental issues ...this review, we address, genetic susceptibilities related ... See full document

... Two review authors (X.S. and X.F.) independently extracted data, and screened the quality and content of the included studies. Variable data of interest were extracted from included studies and entered into a ... See full document

... this being the aggregate effect of pay inflation as measured by the Pay Cost Index (PCI) and the HSCI. This would have seen a 42% uplift in the nominal costs of complications. The effects of applying the HCHS index have ... See full document

... a 2:2:2:1 ratio for a total of 104 ...between- treatment difference (P = ...first 2 weeks and declined over ...all treatment arms. Nine patients had treatment-emergent ... See full document

... of diabetes into a potential novel therapeutic ...with type 2 diabetes, dapagliflozin significantly decreases HbA 1c (by ...the treatment of ...the treatment of diabetes ... See full document

... introduced sulphonylurea derivatives as oral hypoglycemic agents. In 1953, glomerulosis was detected as one of the manifestation of widespread microangiopathy. Presently is recognized as a syndrome characterized by ... See full document

... Regardless, dapagliflozin makes a significant contribu- tion to the range of therapies we require for the optimal management of patients with T2D. Its action is not affected by where a patient lies in the natural history ... See full document

... G. Diabetes prevalence and association with social status - Widening of a social gradient? German national health surveys 1990-1992 and ...1998. Diabetes Research and Clinical ...CA. Diabetes ... See full document

... five percent were from ethnic and racial minority groups known to be at high risk for diabetes. The ILS group was instructed to follow a low-calorie, low-fat diet, with a weight-loss target of 7% of baseline body ... See full document

... of review studies were also examined to find other possible eligible studies for the present ...with type 1 diabetes mellitus or gestational diabetes, studies that did not report information ... See full document

... background treatment with metformin, canagliflozin appears to be superior to sulfonylureas with respect to body weight, blood pressure and risk for hypoglycemia, and to DPP-4 inhibitors in terms of lowering HbA1c, ... See full document

... Abstract: Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type 2 diabetes. Upon injection, ... See full document

... with type 2 diabetes ...of treatment with pioglitazone appear moderate and very few subjects have dropped out of clinical trials because of adverse reactions, and adherence to correct ... See full document

... cotransporter 2 (SGLT2) inhibitor avail- able on the market, offers a unique mechanism of action: it inhibits renal reabsorption of glucose, thus increasing urinary glucose ...we review the potential role ... See full document

... this review is to provide a review of current data of the most recently approved glucagon-like peptide (GLP)-1-receptor agonist, dulaglutide, in the treatment of type 2 ...the ... See full document

... Abstract: Type 2 diabetes is characterized by a progressive decline in beta cell function, with consequent worsening of glycemic ...antihyperglycemic treatment should achieve good and ... See full document

... patient treatment satisfaction. This review appraises the evidence for the view that insulin glargine represents an advance in basal insulin therapy for both type 1 and type 2 ... See full document